[{"orgOrder":0,"company":"Circularis Biotechnologies","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Circular RNA-based Therapeutic","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Circularis Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Circularis Biotechnologies \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"Circularis Biotechnologies \/ Ginkgo Bioworks"}]

Find Clinical Drug Pipeline Developments & Deals by Circularis Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Circularis platform will give Ginkgo the ability to rapidly identify context-specific promoters for cell therapy and circular RNA-based therapeutic applications, such as those that modulate gene expression in the tumor microenvironment.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 04, 2022

                          Lead Product(s) : Circular RNA-based Therapeutic

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Ginkgo Bioworks

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank